| 谢克俭,张琦,夏玉祥,等.131I对Graves病可溶性细胞凋亡蛋白Fas的影响[J].中华放射医学与防护杂志,2006,26(5):493-495.XIE Ke-jian,ZHANG Qi,XIA Yu-xiang,et al.Dynamic study on the influence of 131I treatment on the circulating sFas levels in patients with Graves′disease[J].Chin J Radiol Med Prot,2006,26(5):493-495 |
| 131I对Graves病可溶性细胞凋亡蛋白Fas的影响 |
| Dynamic study on the influence of 131I treatment on the circulating sFas levels in patients with Graves′disease |
| 投稿时间：2005-11-18 |
| DOI： |
| 中文关键词: Graves病 可溶性细胞凋亡蛋白Fas 131I治疗 |
| 英文关键词:Graves disease sFas 131I therapy |
| 基金项目:浙江省教育厅科研基金资助项目(20041050);温州市“新世纪551人才工程”基金资助项目(2004-551-2) |
|
| 摘要点击次数: 3332 |
| 全文下载次数: 2138 |
| 中文摘要: |
| 目的 探讨131I治疗对Graves病(GD)患者循环血可溶性细胞凋亡相关蛋白Fas(sFas)的影响。方法 采用酶联免疫吸附试验(ELISA)和放射免疫分析法(RIA)分别检测52例GD患者131I治疗前及治疗后30、90和180d血清sFas和甲状腺激素水平,并进行相关性分析,30例年龄与性别相匹配的健康者作为正常对照。结果 GD患者血清sFas水平(2.48±1.05)ng/ml显著高于对照组(1.34±0.41)ng/ml(P<0.01);131I治疗180d后,甲状腺功能恢复正常,症状缓解,sFas水平逐渐下降,但仍高于对照组(P<0.05);血清sFas与促甲状腺激素受体抗体(TRAb)呈正相关,与FT3、FTT4和TSH没有相关性。结论 GD患者体内存在sFas异常表达,131I治疗能有效抑制GD患者自身免疫,其治疗前后循环血sFas的动态变化可能与GD发病与转归的病理生理过程有关。 |
| 英文摘要: |
| Objective To study the influence of 131I treatment on the circulating sFas levels of patients with Graves′disease(GD) before and after treatment with 131I. Methods Using the method of enzyme-linked immunosorbent assay(ELISA) and radioimmunoassay, the levels of sFas in serum and thyroid hormone of GD 52 patients were measured before and after 131I therapy while 30 healthy subjects with age and sex matched served as controls, and the results were compared with that of the control group. Results The sFas levels in serum of GD patients were significantly higher than that of the control group(P<0.01). The serum sFas level tended to decrease after the medication of 131I at 180 d, but still higher than that of the normal controls(P<0.05). The concentration of serum sFas was positively correlated with the titers of anti-hyrotropin(TSH) receptor antibody (r= 0.595,P<0.01), but not with the other clinical parameters(FT3, FTT4 and TSH). Conclusions Abnormal concentration of sFas in serum can be observed in patients with GD. 131I therapy would suppress the auto-immune status in GD patients, and the circulating sFas may play a role in the pathogenesis of GD. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|